Crystal Form of Celecoxib: Preparation, Characterization and Dissolution
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) is a cyclooxygenase- 2 inhibitor used in the treatment of arthritis, acute pain, and dysmenorrhoea. Celecoxib is a Biopharmaceutics Classification System (BCS) class II compound whose oral bioavailability is highly limited owing to its poor aqueous solubility. Several polymorphs of celecoxib have been identified as Form I, Form II, and Form III with melting points of about 162.8 °C, 161.5 °C, and 160.8 °C, respectively. Form IV was generated from the precipitated suspension in the presence of HPMC (Hydroxypropyl methylcellulose) and Polysorbate 80. A rapid rate of dissolution is useful because the rate of dissolution of a drug typically increases its bioavailability. The aim of this study was to investigate the possibility of production of new crystal form of celecoxib that has higher solubility than Form III. New crystal form of celecoxib (Form A) has been isolated by recrystallization and characterized by differential scanning calorimetry (DSC), thermogravimetric (TG) analysis and powder X-ray diffractometry (PXRD). Form A was dissolved faster than Form III. At 30 minutes, the dissolution of Form A was 97.3%, whereas the dissolution of Form III was 82.2% (p < 0.1). After storage of three months at 20 °C, in 24% RH (Relative Humidity), the crystal form was not transformed.
Abstract
Celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) is a cyclooxygenase- 2 inhibitor used in the treatment of arthritis, acute pain, and dysmenorrhoea. Celecoxib is a Biopharmaceutics Classification System (BCS) class II compound whose oral bioavailability is highly limited owing to its poor aqueous solubility. Several polymorphs of celecoxib have been identified as Form I, Form II, and Form III with melting points of about 162.8 °C, 161.5 °C, and 160.8 °C, respectively. Form IV was generated from the precipitated suspension in the presence of HPMC (Hydroxypropyl methylcellulose) and Polysorbate 80. A rapid rate of dissolution is useful because the rate of dissolution of a drug typically increases its bioavailability. The aim of this study was to investigate the possibility of production of new crystal form of celecoxib that has higher solubility than Form III. New crystal form of celecoxib (Form A) has been isolated by recrystallization and characterized by differential scanning calorimetry (DSC), thermogravimetric (TG) analysis and powder X-ray diffractometry (PXRD). Form A was dissolved faster than Form III. At 30 minutes, the dissolution of Form A was 97.3%, whereas the dissolution of Form III was 82.2% (p < 0.1). After storage of three months at 20 °C, in 24% RH (Relative Humidity), the crystal form was not transformed.
참고문헌 (23)
- Fiese, E. F., "The theory and practice of industrial pharmacy", pp.171~ (1986), Lea & Febiger
- Wells, J., "Pharmaceutics", pp.113~ (2002), Churchill Livingstone
- "Q6A International Conference on Harmonization; Guidance on Q6A Specifications", Federal Register, 65, pp.83041~ (2000)
- Kim, S. K., , J. Therm. Anal. Calorim., 127, pp.1715~ (2017)[DOI]
- Griesser, U. J., , J. Therm. Anal. Calorim., 77, pp.511~ (2004)[DOI]
- Dichi, E., , J. Therm. Anal. Calorim., 115, pp.1551~ (2014)[DOI]
- Seo, H. O., , J. Therm. Anal. Calorim., 120, pp.749~ (2015)[DOI]
- Tak, S. R., , J. Therm. Anal. Calorim., 123, pp.2477~ (2016)[DOI]
- Di, M. P., , Eur. J. Pharm. Sci., 14, pp.293~ (2001)[DOI]
- Brittain, H. G., "Polymorphism in pharmaceutical solids", pp.227~ (1999), Marcel Dekker
- Simon, L. S., , Arthritis Rheum., 41, pp.1591~ (1998)[DOI]
- Chuang, H. C., , Mol. Cancer., 7, pp.38~ (2008)
- Ferro, L. J., "US 7476744 B2", ~ (2009)
- Morissette, S. L., , Adv. Drug Deliv. Rev., 56, pp.275~ (2004)[DOI]
- Chawla, G., , Eur. J. Pharm. Sci., 20, pp.305~ (2003)[DOI]
- Hageman, M. J., "US 6964978 B2", ~ (2005)
- Paradkar, A. R., , Drug Dev. Ind. Pharm., 29, pp.739~ (2003)[DOI]
- "Dissolution methods" (2016)
- Lu, G. W., , J. Pharm. Sci., 95, pp.305~ (2006)[DOI]
- Grzybowska, K., , J. Phys. Chem. B., 114, pp.12792~ (2010)[DOI]
- Gupta, P., , Pharm. Res., 21, pp.1762~ (2004)[DOI]
- Guillory, J. K., "Polymorphism in pharmaceutical solids", pp.183~ (1999), Marcel Dekker
- Hendriksen, B. A., , Int. J. Pharm., 60, pp.243~ (1990)[DOI]